(INCY) Incyte Corporation BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(INCY) Incyte Corporation Bundle
See the Bigger Picture
This Incyte Corporation BCG Matrix helps you see how the company’s products or business units may rank across Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Opzelura 1.5% cream atopic dermatitis
Atopic dermatitis is a large, fast-growing market, affecting about 16.5 million U.S. adults and 9.6 million children. Opzelura 1.5% cream kept gaining prescriptions into 2025 and became one of Incyte Corporation’s key growth drivers, with U.S. product revenue reaching $1.1 billion in 2024 across the brand’s uses. That mix of high growth and strong share fits the Star quadrant.
Opzelura 1.5% cream nonsegmental vitiligo
Opzelura 1.5% cream is Incyte Corporation’s second growth engine, with total product revenue of $730 million in 2024 and nonsegmental vitiligo as a key driver. Incyte’s 2024 annual report said Opzelura reached $597 million in ruxolitinib cream sales, up sharply year over year, while vitiligo remains a growing branded-dermatology market. That mix of rapid growth and share gains fits Star status.
Jakafi chronic graft-versus-host disease
Jakafi's cGVHD franchise stays a Star: chronic graft-versus-host disease is a durable post-transplant market, and ruxolitinib is the first FDA-approved therapy for steroid-refractory cGVHD in patients 12 and older. Incyte says Jakafi remains a top growth driver, with cGVHD adding long-duration use beyond the 2.5-year median follow-up seen in pivotal trials. Strong share in a growing transplant-support segment fits the Star box.
Zynyz Merkel cell carcinoma
Merkel cell carcinoma is a very small but active immuno-oncology niche, with about 3,000 U.S. cases a year and a high unmet-need profile. Zynyz gives Incyte Corporation a marketed PD-1 asset in this growing space, so if adoption and share hold, it can fit Star logic.
- Rare disease, but treatment demand stays active
- Marketed PD-1 asset supports share capture
- Strong fit if uptake stays durable
Incyte Corporation’s edge is that Zynyz is not just a pipeline story; it is already commercial in a niche where durable responses matter. That makes it more Star-like than a pure question-mark asset if growth keeps tracking above the low base.
Zynyz anal cancer
Zynyz gives Incyte Corporation a second commercial growth lane for retifanlimab, alongside its existing oncology use. Anal cancer is a small but still addressable market, and immune checkpoint use keeps expanding in later-line and frontline settings. That launch mix fits a Star profile: high growth potential plus rising adoption.
- Second growth engine for retifanlimab
- Anal cancer market still expanding
- Immunotherapy use is rising
- Supports Star classification
Incyte’s Star Assets: Opzelura, Jakafi cGVHD, and Zynyz Drive Growth
Incyte Corporation’s Stars are Opzelura, Jakafi in cGVHD, and Zynyz. Opzelura drove $1.1 billion in U.S. product revenue in 2024, while Jakafi’s cGVHD use and Zynyz’s rare-cancer launches keep growth tied to real demand. These assets pair rising share with expanding markets, which is the core Star profile.
| Asset | Key data | BCG fit |
|---|---|---|
| Opzelura | $1.1B U.S. revenue, 2024 | Star |
| Jakafi cGVHD | Durable transplant use | Star |
| Zynyz | Commercial rare-cancer asset | Star |
What is included in the product
Detailed Word Document
Incyte Corporation BCG Matrix maps its drugs by growth and share to guide invest, hold, or divest decisions.
Editable Excel File
One-page BCG Matrix for Incyte Corporation to quickly spot portfolio pain points and growth bets
Reference Sources
Lists credible sources behind Incyte assumptions, boosting trust, speeding diligence, and supporting faster, better decisions.
Cash Cows
Jakafi myelofibrosis
Jakafi’s myelofibrosis franchise is Incyte Corporation’s core cash engine, with mature demand and high penetration in a specialty market. Incyte Corporation reported Jakafi net product revenue of $2.4 billion in 2024, and myelofibrosis remains the key driver of that base. Slower growth but strong share makes it a clear Cash Cow in the BCG matrix.
Jakafi polycythemia vera
Polycythemia vera is a mature Jakafi indication, so growth is steadier than in new launches. Jakafi still anchors Incyte’s cash engine, with 2024 net product revenue of about $2.9 billion and broad use across established patients.
In this market, Incyte wins more on retention than on rapid new-patient gains, which fits a Cash Cow profile. Stable prescribing and recurring refill demand support strong cash flow even as the segment grows at a measured pace.
Ruxolitinib ex-US royalties
Incyte Corporation’s ex-U.S. ruxolitinib royalties from Novartis fit the Cash Cow profile: the drug has been on market for years, so demand is mature and incremental selling spend is low. Royalty income is high-margin, and Incyte Corporation’s 2025 filings still show this stream as a steady contributor backed by an established product base.
Iclusig chronic myeloid leukemia
Iclusig fits a Cash Cow profile: CML is a long-lived but low-growth market, with incidence around 1 to 2 cases per 100,000 people a year, so demand is steady rather than expanding fast. Incyte already has an established asset here, not a new launch driver, which supports mature niche cash generation.
- Slow CML growth limits upside
- Established brand supports steady sales
- Mature niche, not high-growth
Iclusig Ph-positive acute lymphoblastic leukemia
Incyte Corporation’s Iclusig in Ph-positive acute lymphoblastic leukemia sits in a small, niche market with limited patient volume. The drug is already commercial, so it serves a defined pool instead of chasing fast label expansion. That makes the ALL use case a cash cow: mature demand, repeat prescribing, and steady revenue rather than high growth.
Small, specialized Ph-positive ALL market
Commercial product with an established patient base
Mature indication supports steady cash flow
Jakafi Powers Incyte’s Steady Cash Flow
Jakafi is Incyte Corporation’s main Cash Cow, with 2024 net product revenue of $2.4 billion and a mature myelofibrosis base. Polycythemia vera and other established uses keep demand steady, so growth is slower but cash flow stays strong. Ex-U.S. ruxolitinib royalties from Novartis and Iclusig add low-cost, repeat revenue from long-lived markets.
| Cash Cow | 2024/2025 signal | Why it fits |
|---|---|---|
| Jakafi | $2.4B revenue | Mature, high-share |
| Ruxolitinib royalties | Steady 2025 stream | High-margin, low spend |
| Iclusig | Niche, stable demand | Repeat prescribing |
Preview the Actual Deliverable
Incyte Corporation Reference Sources
The Incyte Corporation BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo pages or placeholder content—just the complete, professionally formatted report. It’s ready for immediate use in analysis, presentations, or strategic planning.
Dogs
Parsaclisib follicular lymphoma
Parsaclisib stays a development-stage asset, so Incyte Corporation has no meaningful commercial base to defend. Follicular lymphoma is crowded, with established anti-CD20, BTK, and CAR-T options, so share is still thin. With no disclosed 2025 sales and weak growth visibility, Parsaclisib fits the Dog bucket.
Parsaclisib marginal zone lymphoma
Parsaclisib in marginal zone lymphoma sits in a small niche: MZL is about 3% to 5% of non-Hodgkin lymphoma, and treatment is already crowded with rituximab-based regimens, BTK inhibitors, and lenalidomide-rituximab. Parsaclisib did not build clear market leadership or strong share. That weak uptake fits the Dog quadrant for Incyte Corporation.
Parsaclisib mantle cell lymphoma
Parsaclisib in mantle cell lymphoma fits a Dog: MCL is a rare, hard-to-treat lymphoma, making up about 3%-10% of non-Hodgkin lymphoma cases, so the addressable market is small. Parsaclisib has no approved standalone revenue stream in this use case, and with weak growth visibility plus low share, it adds little to Incyte Corporation's BCG profile.
Legacy PI3K portfolio
Incyte Corporation’s legacy PI3K portfolio fits Dogs: the class has faced strong safety and efficacy pushback, and by end-2025 these older assets showed little visible commercial scale. With weak demand economics and shrinking industry use, the portfolio no longer looks like a growth driver.
Incyte Corporation should treat PI3K as a harvest-or-exit bucket, not a capital priority.
- Limited end-2025 scale
- Weak market demand
- High clinical risk
- Low BCG growth fit
Non-core legacy research assets
Incyte Corporation's non-core legacy research assets fit Dogs because early-stage programs do not yet produce sales and keep R&D tied up before any market share is proven. Until a program shows clear clinical and commercial differentiation, it stays a low-return use of capital.
- Pre-revenue and cash-consuming.
- No proven market share yet.
- Stay Dogs until differentiation appears.
Incyte Corporation should keep pruning these assets, since the value case only changes after strong data, a clear label path, or partner demand. That is the clean test for moving them out of Dogs.
Incyte’s Dog Assets Face Weak Sales and Fierce Competition
Incyte Corporation’s Dogs are mostly Parsaclisib and other legacy PI3K assets: no disclosed 2025 sales, weak share, and crowded niches. MZL is about 3%-5% of non-Hodgkin lymphoma and MCL about 3%-10%, but both have stronger rivals, so growth stays thin and capital should be harvested or exited.
| Asset | 2025 read | BCG |
|---|---|---|
| Parsaclisib | No disclosed sales | Dog |
| Legacy PI3K | Weak demand | Dog |
Question Marks
Itacitinib newly diagnosed chronic graft-versus-host disease
Chronic graft-versus-host disease affects about 30% to 50% of allogeneic stem cell transplant survivors, so newly diagnosed cGVHD is a real growth market for Incyte Corporation. Itacitinib is still in development, so it has not built commercial share yet. That mix of high unmet need and low current penetration is classic Question Mark territory.
Retifanlimab non-small cell lung cancer
NSCLC makes up about 85% of lung cancers and is one of oncology’s biggest markets, with 2.48 million new lung cancer cases worldwide in 2022. Retifanlimab is still building its NSCLC case through ongoing clinical trials, so Incyte Corporation has not yet turned that large demand into meaningful share. That mix of big market, low share, and development risk fits a Question Mark in the BCG Matrix.
Retifanlimab MSI-high endometrial cancer
Endometrial cancer immunotherapy is expanding, with dMMR/MSI-high tumors making up about 25%-30% of cases and driving stronger demand for checkpoint drugs. Retifanlimab is still not a dominant choice in this niche, so its BCG position fits a Question Mark. The opportunity is real, but share is unproven versus established PD-1 leaders.
Pemigatinib bladder cancer
Bladder cancer is a large solid-tumor market, with about 614,000 new cases and 220,000 deaths worldwide in 2022, but Pemigatinib is still in expansion testing, not broad commercial leadership. That makes it a Question Mark in Incyte Corporation's BCG Matrix, because the drug has growth upside but no proven scale in this setting yet. The key issue is conversion: trial progress must turn into approval and share.
- Large market, still early-stage use
- Expansion testing, not cash-cow status
- Question Mark fits best
Pemigatinib myeloproliferative syndrome
Pemigatinib in myeloproliferative syndrome fits the Question Mark bucket: it is a possible label expansion, not a mature franchise. The market is still being defined, and Incyte has little current share in this use because it remains investigational.
- Label expansion upside
- Low current share
- Market still forming
That leaves the asset with real development optionality, but limited near-term revenue visibility.
Incyte’s Question Marks Target Big Markets, But Commercial Proof Is Still Thin
Incyte Corporation’s Question Marks are mostly late-stage or investigational oncology assets with big markets but weak share: cGVHD, NSCLC, endometrial cancer, bladder cancer, and label-expansion uses for pemigatinib. The common pattern is high unmet need, but no clear commercial scale yet.
| Asset | Market signal | BCG |
|---|---|---|
| Itacitinib | 30%-50% cGVHD | Question Mark |
| Retifanlimab | 2.48M lung cases | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.